Neuroprotective Compound Stabilizes Cognitive Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis are largely ineffective in preventing or reversing the progression of these conditions, with existing therapies mainly focusing on symptom management rather than addressing the underlying causes of neuronal damage and degeneration.
Innovation Solution
A compound of formula (I), specifically designed to target neurodegenerative disorders, which includes a glucopyranose or glucofuranose moiety and an amino acid, is used to treat or prevent neurodegenerative disorders by promoting neuronal survival, reducing neurotoxicity, and enhancing myelination, thereby addressing the root causes of these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative disorders are used, then symptom management is achieved, but the underlying causes of neuronal damage and degeneration are not addressed
Solution Approach 1:
The compound converts harmful factors into beneficial effects by: (1) converting amyloidogenic peptides into non-toxic forms through inhibition of aggregation, (2) transforming reactive oxygen species from damaging agents into controlled signaling molecules through antioxidant activity, (3) converting inflammatory responses from destructive forces into protective immune responses through modulation of cytokine production. This principle directly addresses the contradiction by transforming the disease-causing mechanisms into therapeutic pathways.
Solution Approach 2:
The compound represents a composite molecular structure combining multiple functional groups in one molecule: (1) a core structure with specific stereochemistry, (2) hydrophobic regions for membrane interaction, (3) hydrophilic regions for solubility, (4) functional groups for enzymatic inhibition, and (5) antioxidant moieties. This composite structure enables simultaneous addressing of multiple disease mechanisms including protein aggregation, oxidative stress, and inflammation, thereby improving treatment effectiveness while targeting root causes.
2Ease of operation
If existing therapies focus on symptom management, then immediate relief is provided, but prevention of disease progression is not achieved
Solution Approach 1:
The compound performs preliminary protective actions before irreversible neuronal damage occurs by: (1) preventing amyloid fibril formation through early intervention with monomeric peptides, (2) providing antioxidant protection before oxidative damage accumulates, (3) inhibiting inflammatory cascades before neuronal death ensues. This preliminary action prevents disease progression while maintaining ease of administration through oral or injectable formulations.
Solution Approach 2:
The compound enables continuous protective action against neurodegeneration through mechanisms that persist throughout the disease course: (1) sustained inhibition of amyloid aggregation through binding to peptide monomers and oligomers, (2) continuous antioxidant activity through regeneration of endogenous antioxidants, (3) ongoing anti-inflammatory effects through modulation of immune cell function. This continuous action addresses both symptom management and disease progression prevention.
3Ease of operation
If no known cure for multiple sclerosis exists, then current treatments can only improve function after attacks, but permanent neurological problems occur as the disease advances
Solution Approach 1:
The compound applies preliminary anti-action to prevent the harmful effects of MS by: (1) preemptively inhibiting amyloid-beta aggregation that contributes to neurodegeneration in MS, (2) providing antioxidant protection against oxidative stress from immune infiltration, (3) reducing inflammatory damage before demyelination and axonal degeneration occur. This preliminary protection prevents permanent neurological problems while maintaining functional improvement capabilities.
4Reliability
If alpha-synuclein aggregates are deposited in neuronal and glial cells, then neurodegeneration occurs, but the function of alpha-synuclein is not well understood
Solution Approach 1:
The compound extracts or removes the harmful aggregating property of alpha-synuclein through: (1) binding to alpha-synuclein monomers and oligomers to prevent aggregation, (2) promoting disaggregation of existing aggregates through competitive binding, (3) facilitating clearance of aggregated protein through enhanced proteasomal degradation. This extraction of the harmful aggregating property preserves neuronal function while eliminating neurotoxicity.
Data Source
AI summary
The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.